Hepatitis C virus (HCV) is the most common cause of chronic liver disease, cirrhosis,
and hepatocellular carcinoma (HCC) in the United States and infects an estimated 170
million people worldwide. In the United States, overall hepatitis C prevalence is
1.8% and is higher in African Americans and Hispanics than it is in white Americans.
The age distribution places 65% of all subjects with anti-HCV antibodies between 30
and 49 years of age. Before serological screening of blood products was initiated,
hepatitis C was most commonly transmitted by transfusion of contaminated blood products,
but now it is acquired primarily via intravenous drug use. Only 10 to 25% of infected
adult patients spontaneously resolve their infection, and the remaining 75% remain
persistently viremic and often asymptomatic. Progression of liver disease in 20 to
30% of patients can lead to compensated and eventually decompensated cirrhosis or
hepatocellular carcinoma, or both. This article looks briefly at the epidemiology
and natural history of hepatitis C.
KEYWORDS
Chronic hepatitis C - natural history
REFERENCES
- 1
Di Bisceglie A M.
Hepatitis C.
Lancet.
1998;
351
351-355
- 2
Centers for Disease Control and Prevention (CDC) .
Recommendations for prevention and control of hepatitis C virus (HCV) infection and
HCV-related disease.
MMWR Morb Mortal Wkly Rep.
1998;
47
1-40
- 3
, Anonymous
Global surveillance and control of hepatitis C. Report of a WHO Consultation organized
in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.
J Viral Hepat.
1999;
6
35-47
- 4 McQuillan G, Alter M, Moyer L, Lambert S, Margolis H. A population based serologic
study of hepatitis C virus infection in the United States. In: Rizzetto M, Purcell
RH, Gerin JL, et al Viral Hepatitis and Liver Disease. Turin; Edizioni Minerva Medica
1997: 267-270
- 5
Alter M, Kruszon-Moran D, Nainan O et al..
The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.
N Engl J Med.
1999;
341
556-562
- 6
Armstrong G L, Alter M J, McQuillan G M, Margolis H S.
The past incidence of hepatitis C virus infection: implications for the future burden
of chronic liver disease in the United States.
Hepatology.
2000;
31
777-782
- 7
, Anonymous
Management of hepatitis C.
NIH Consens Statement.
1997;
15
1-41
- 8
Davis G L, Albright J E, Cook S F, Rosenberg D M.
Projecting the future healthcare burden from hepatitis C in the United States.
Hepatology.
1998;
28
390A
- 9
Wong J B, McQuillan G M, McHutchison J G, Poynard T.
Estimating future hepatitis C morbidity, mortality, and costs in the United States.
Am J Public Health.
2000;
90
1562-1569
- 10
Kim W R, Gross Jr J B, Poterucha J J, Locke III G R, Dickson E R.
Outcome of hospital care of liver disease associated with hepatitis C in the United
States.
Hepatology.
2001;
33
201-206
- 11
Spaulding A, Greene C, Davidson K, Schneidermann M, Rich J.
Hepatitis C in state correctional facilities.
Prev Med.
1999;
28
92-100
- 12
Vlahov D, Nelson K E, Quinn D C, Kendig N.
Prevalence and incidence of hepatitis C virus infection among male prison inmates
in Maryland.
Eur J Epidemiol.
1993;
9
566-569
- 13
Austin G E, Jensen B, Leete J et al..
Prevalence of hepatitis C virus seropositivity among hospitalized US veterans.
Am J Med Sci.
2000;
319
353-359
- 14
Cheung R C.
Epidemiology of hepatitis C virus infection in American veterans.
Am J Gastroenterol.
2000;
95
740-747
- 15
Simmonds P, Holmes E C, Cha T A et al..
Classification of hepatitis C virus into six major genotypes and a series of subtypes
by phylogenetic analysis of the NS-5 region.
J Gen Virol.
1993;
74
2391-2399
- 16
Honda M, Kaneko S, Sakai A et al..
Degree of diversity of hepatitis C virus quasispecies and progression of liver disease.
Hepatology.
1994;
20
1144-1151
- 17
Zein N N, Rakela J, Krawitt E L et al..
Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and
response to interferon therapy. Collaborative Study Group.
Ann Intern Med.
1996;
125
634-639
- 18
Ferreira-Gonzalez A, Shiffman M L.
Diagnostic testing of hepatitis C virus infection.
Semin Liver Dis.
2004;
24(suppl 2)
9-18
- 19
Shakil A O, Conry-Cantilena C, Alter H J et al..
Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical,
virologic, and histologic features.
Ann Intern Med.
1995;
123
330-337
- 20
Seeff L B.
Natural history of hepatitis C.
Am J Med.
1999;
107
10S-15S
- 21
Boyer N, Marcellin P.
Natural history of hepatitis C and the impact of anti-viral therapy.
Forum (Genova).
2000;
10
4-18
- 22
Jaeckel E, Cornberg M, Wedemeyer H et al..
Treatment of acute hepatitis C with interferon alfa-2b.
N Engl J Med.
2001;
345
1452-1457
- 23
Mathurin P, Moussalli J, Cadranel J F et al..
Slow progression rate of fibrosis in hepatitis C virus patients with persistently
normal alanine transaminase activity.
Hepatology.
1998;
27
868-872
- 24
Kenny-Walsh E.
Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin.
Irish Hepatology Research Group.
N Engl J Med.
1999;
340
1228-1233
- 25
Asselah T, Martinot M, Cazals Hatem D et al..
Hypervariable region 1 quasispecies in HCV genotypes 1b and 3 infected patients with
normal and abnormal ALT levels.
J Virol Hepatol.
2002;
9
29-35
- 26
Alter M J, Margolis H S, Krawczynski K et al..
The natural history of community-acquired hepatitis C in the United States. The Sentinel
Counties Chronic non-A, non-B Hepatitis Study Team.
N Engl J Med.
1992;
327
1899-1905
- 27
Diepolder H M, Gerlach J T, Zachoval R et al..
Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis
C virus infection.
J Virol.
1997;
71
6011-6019
- 28
Wong D K, Dudley D D, Afdhal N H et al..
Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses
in a cohort of persons with chronic infection.
J Immunol.
1998;
160
1479-1488
- 29
Missale G, Bertoni R, Lamonaca V et al..
Different clinical behaviors of acute hepatitis C virus infection are associated with
different vigor of the anti-viral cell-mediated immune response.
J Clin Invest.
1996;
98
706-714
- 30
Diepolder H M, Zachoval R, Hoffmann R M et al..
Possible mechanism involving T-lymphocyte response to non-structural protein 3 in
viral clearance in acute hepatitis C virus infection.
Lancet.
1995;
346
1006-1007
- 31
Hiroishi K, Kita H, Kojima M et al..
Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection.
Hepatology.
1997;
25
705-712
- 32
Zinkernagel R M.
Immunology taught by viruses.
Science.
1996;
271
173-178
- 33
Tong M J, el-Farra N S, Reikes A R, Co R L.
Clinical outcomes after transfusion-associated hepatitis C.
N Engl J Med.
1995;
332
1463-1466
- 34
Poynard T, Bedossa P, Opolon P.
Natural history of liver fibrosis progression in patients with chronic hepatitis C.
The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.
Lancet.
1997;
349
825-832
- 35
Seeff L B, Hollinger F B, Alter H J et al..
Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type
C hepatitis: A National Heart, Lung, and Blood Institute Collaborative Study.
Hepatology.
2001;
33
455-463
- 36
Shehab T, Orrego M, Lok A.
Spectrum of liver disease in hepatitis C patients presenting to primary care clinics.
Gastroenterology.
2001;
120
A369
- 37
Fattovich G, Giustina G, Degos F et al..
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up
study of 384 patients.
Gastroenterology.
1997;
112
463-472
- 38
Shiffman M L.
Improvement in liver histopathology associated with interferon therapy in patients
with chronic hepatitis C.
Viral Hepatol Rev.
1999;
5
27-43
- 39
Mohamed A E, Ven D, Al Karawi M A.
Dual infection with hepatitis C and B viruses: clinical and histologic study in Saudi
patients.
Hepatogastroenterology.
1997;
44
1404-1406
- 40
Zarski J-P, Bohn B, Bastie A.
Characteristics of patients with dual infection by hepatitis B and C viruses.
J Hepatol.
1998;
28
27-33
- 41
Sulkowski M S, Mast E E, Seeff L B, Thomas D L.
Hepatitis C virus infection as an opportunistic disease in persons infected with human
immunodeficiency virus.
Clin Infect Dis.
2000;
30(Suppl 1)
S77-S84
- 42
Boyer N, Marcellin P.
Pathogenesis, diagnosis and management of hepatitis C.
J Hepatol.
2000;
32(Suppl 1)
98-112
- 43
Zylberberg H, Rimaniol A C, Pol S et al..
Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with
histological fibrosis and activity.
J Hepatol.
1999;
30
185-191
- 44
Perrella A, Perrella, Conca P, Tarantino G.
CD8+/CD38+: immune activity and clinical significance in HCV patients with and without
interferon therapy.
Eur Rev Med Pharmacol Sci.
2000;
4
127-131
- 45
Shiffman M L, Stewart C A, Hofmann C M et al..
Chronic infection with hepatitis C virus in patients with elevated or persistently
normal serum alanine aminotransferase levels: comparison of hepatic histology and
response to interferon therapy.
J Infect Dis.
2000;
182
1595-1601
- 46
El-Serag H B, Mason A C.
Rising incidence of hepatocellular carcinoma in the United States N Engl.
J Med.
1999;
340
745-750
- 47 Godley P A, Sandler R S. Liver cancer. In: Everhart JE Digestive Diseases in the
United States: Epidemiology and Impact. Washington, DC; National Institutes of Health
1994: 227-241
Nezam H AfdahlM.D.
Liver Center, Beth Israel Deaconess Medical Center
330 Brookline Avenue
Boston, MA 02215
Email: nafdhal@caregroup.harvard.edu
